"Providing New Treatment Opportunities"

The Ministry of Food and Drug Safety announced on July 10, 2026, that it had approved the imported orphan drug "Joenza Tablets (leniolisib phosphate)" for the treatment of patients with activated PI3K delta syndrome (APDS).


APDS is a rare disease characterized by immune deficiency, recurrent infections, and lymphoproliferation, caused by a genetic abnormality in PI3K delta, which is responsible for intracellular signal transduction.

Joenja Tablets Approved in Korea for Treatment of Rare Disease APDS View original image

Joenza Tablets exert a therapeutic effect by selectively inhibiting PI3K delta, thereby normalizing excessive intracellular signaling. The drug is expected to provide new treatment opportunities for patients with rare diseases for which no therapies currently exist.


Previously, the Ministry designated Joenza Tablets as the 27th product under the Global Innovative Product Fast-Track (GIFT) program and conducted an expedited review to enable its rapid introduction to the medical field.



The Ministry stated, "We will continue to do our utmost, based on regulatory science expertise, to ensure that therapies with sufficiently verified safety and efficacy are reviewed and approved quickly, thereby expanding treatment opportunities."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing